[{"id":"243bbd2b-9fa8-4a47-8997-af40c6654b26","acronym":"SEL-TH-1601","url":"https://clinicaltrials.gov/study/NCT03095248","created_at":"2021-01-18T15:15:00.040Z","updated_at":"2024-07-02T16:34:26.978Z","phase":"Phase 2","brief_title":"Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors","source_id_and_acronym":"NCT03095248 - SEL-TH-1601","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Suspended","enrollment":" Enrollment 34","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-12"},{"id":"6076406a-9463-43ad-ba76-13f9a5a2bd1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445288","created_at":"2021-01-18T05:59:39.581Z","updated_at":"2024-07-02T16:34:36.842Z","phase":"","brief_title":"Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","source_id_and_acronym":"NCT01445288","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • TNFA","pipe":"","alterations":" ","tags":["VEGFA • TNFA"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/05/2006","start_date":" 12/05/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-10"},{"id":"67575df3-fe79-49cd-97ab-2aa59bfde6c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02359565","created_at":"2021-01-18T11:13:52.172Z","updated_at":"2024-07-02T16:34:27.667Z","phase":"Phase 1","brief_title":"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma","source_id_and_acronym":"NCT02359565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" TMB-H","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/22/2015","start_date":" 05/22/2015","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-10"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2024-07-02T16:34:37.703Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-06-06"},{"id":"2d640cff-e8d0-459a-ae6a-92adad2804d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173950","created_at":"2022-04-11T23:54:29.961Z","updated_at":"2024-07-02T16:34:58.739Z","phase":"Phase 2","brief_title":"Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers","source_id_and_acronym":"NCT03173950","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCOR • FOXR2","pipe":"","alterations":" ","tags":["BCOR • FOXR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 07/13/2017","start_date":" 07/13/2017","primary_txt":" Primary completion: 04/21/2026","primary_completion_date":" 04/21/2026","study_txt":" Completion: 04/21/2027","study_completion_date":" 04/21/2027","last_update_posted":"2024-06-05"},{"id":"b59b27f1-de71-4f26-8ce2-01742271e9ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161519","created_at":"2023-12-08T15:15:31.906Z","updated_at":"2024-07-02T16:34:38.055Z","phase":"Phase 1/2","brief_title":"PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications","source_id_and_acronym":"NCT06161519","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLX038"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 11/14/2028","primary_completion_date":" 11/14/2028","study_txt":" Completion: 11/14/2033","study_completion_date":" 11/14/2033","last_update_posted":"2024-06-05"},{"id":"b5925ff8-a414-4e5c-8129-fb6140d88f40","acronym":"PNOC028","url":"https://clinicaltrials.gov/study/NCT05887882","created_at":"2024-06-08T04:17:18.068Z","updated_at":"2024-07-02T16:34:59.247Z","phase":"Phase 1","brief_title":"Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors","source_id_and_acronym":"NCT05887882 - PNOC028","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-04"},{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2024-07-02T16:34:59.830Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"1ba7d423-e8de-4bf4-9f12-f7ec8c7c5db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03526250","created_at":"2021-01-18T17:22:05.437Z","updated_at":"2024-07-02T16:35:02.332Z","phase":"Phase 2","brief_title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03526250","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-21"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2024-07-02T16:35:02.388Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-21"},{"id":"82dcc018-99ce-47f7-8c3b-045c9ebf3e1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220035","created_at":"2021-01-18T15:53:33.764Z","updated_at":"2024-07-02T16:35:02.750Z","phase":"Phase 2","brief_title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03220035","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-17"},{"id":"87923196-97d9-4e54-a07f-3d2558fab429","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101905","created_at":"2021-01-18T09:41:49.492Z","updated_at":"2024-07-02T16:35:07.246Z","phase":"Phase 1","brief_title":"Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT02101905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/13/2014","start_date":" 03/13/2014","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2024-04-29"},{"id":"84233739-ed53-4cf9-9895-5c8bd3e952d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03043391","created_at":"2021-01-18T14:59:13.296Z","updated_at":"2024-07-02T16:35:10.938Z","phase":"Phase 1","brief_title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","source_id_and_acronym":"NCT03043391","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2024-04-08"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2024-07-02T16:35:10.934Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric CNS Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • CD4","pipe":"","alterations":" ","tags":["TMB • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-08"},{"id":"ded28c5c-3c55-451b-9869-82a9bdbbf53d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04903080","created_at":"2021-05-26T15:53:11.190Z","updated_at":"2024-07-02T16:35:11.248Z","phase":"Phase 1","brief_title":"HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma","source_id_and_acronym":"NCT04903080","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 07/20/2028","primary_completion_date":" 07/20/2028","study_txt":" Completion: 07/20/2043","study_completion_date":" 07/20/2043","last_update_posted":"2024-04-05"},{"id":"fca0acc3-ee52-4102-a447-7fd22d0a32ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162732","created_at":"2021-01-18T10:04:10.523Z","updated_at":"2024-07-02T16:35:11.152Z","phase":"","brief_title":"Molecular-Guided Therapy for Childhood Cancer","source_id_and_acronym":"NCT02162732","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-05"},{"id":"3dd7c2f3-5edb-4afd-aab6-f0b5ef867dad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796273","created_at":"2021-01-18T18:46:15.719Z","updated_at":"2024-07-02T16:35:11.784Z","phase":"Phase 1","brief_title":"Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases","source_id_and_acronym":"NCT03796273","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" KDR • CD24 • POU5F1 • VEGFC","pipe":"","alterations":" ","tags":["KDR • CD24 • POU5F1 • VEGFC"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-04-03"},{"id":"413fd329-dd85-45a6-b07c-a0fee98c2f35","acronym":"","url":"https://clinicaltrials.gov/study/NCT04743661","created_at":"2021-02-08T13:52:25.106Z","updated_at":"2024-07-02T16:35:12.204Z","phase":"Phase 2","brief_title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","source_id_and_acronym":"NCT04743661","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/04/2022","start_date":" 04/04/2022","primary_txt":" Primary completion: 10/30/2029","primary_completion_date":" 10/30/2029","study_txt":" Completion: 10/30/2030","study_completion_date":" 10/30/2030","last_update_posted":"2024-03-29"},{"id":"887bbe2f-1a3b-4e65-a040-88b688a3dcae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04408092","created_at":"2022-12-21T11:58:16.703Z","updated_at":"2024-07-02T16:35:14.571Z","phase":"Phase 1","brief_title":"Study of the Effect of GM-CSF on Macrophages in Ependymoma","source_id_and_acronym":"NCT04408092","lead_sponsor":"University of Colorado, Denver","biomarkers":" AIF1","pipe":"","alterations":" ","tags":["AIF1"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 06/25/2013","start_date":" 06/25/2013","primary_txt":" Primary completion: 09/21/2021","primary_completion_date":" 09/21/2021","study_txt":" Completion: 07/21/2023","study_completion_date":" 07/21/2023","last_update_posted":"2024-03-15"},{"id":"002e6ccc-3a81-4cfa-b237-64f0c73db083","acronym":"INTUITT-NF2","url":"https://clinicaltrials.gov/study/NCT04374305","created_at":"2021-01-18T21:07:59.980Z","updated_at":"2024-07-02T16:35:15.097Z","phase":"Phase 2","brief_title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","source_id_and_acronym":"NCT04374305 - INTUITT-NF2","lead_sponsor":"Scott R. Plotkin, MD, PhD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-03-13"},{"id":"8692edc5-36b9-41d3-83ee-d4803fca127c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05835687","created_at":"2023-04-28T15:04:55.022Z","updated_at":"2024-07-02T16:35:14.889Z","phase":"Phase 1","brief_title":"Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors","source_id_and_acronym":"NCT05835687","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e B7-H3 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/27/2023","start_date":" 04/27/2023","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-03-13"},{"id":"ffe96379-a55d-4c21-b2bf-0bb984a6f16f","acronym":"STIR Trial","url":"https://clinicaltrials.gov/study/NCT02100891","created_at":"2021-01-18T09:42:21.170Z","updated_at":"2024-07-02T16:35:15.156Z","phase":"Phase 2","brief_title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors","source_id_and_acronym":"NCT02100891 - STIR Trial","lead_sponsor":"Monica Thakar","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 03/20/2013","start_date":" 03/20/2013","primary_txt":" Primary completion: 06/08/2020","primary_completion_date":" 06/08/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2024-03-12"},{"id":"10e34025-5747-4dee-b161-fb7ad52933b1","acronym":"INFORM2 NivEnt","url":"https://clinicaltrials.gov/study/NCT03838042","created_at":"2021-01-18T18:56:47.273Z","updated_at":"2024-07-02T16:35:20.359Z","phase":"Phase 1/2","brief_title":"INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies","source_id_and_acronym":"NCT03838042 - INFORM2 NivEnt","lead_sponsor":"University Hospital Heidelberg","biomarkers":" PD-L1 • TMB • MYC","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Jingzhuda (entinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 05/26/2020","start_date":" 05/26/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-02-07"}]